Nitrofurantoin

證據等級: L5

預測適應症: 10 個

Nitrofurantoin: From Urinary Tract Infection to Rheumatoid Arthritis

One-Sentence Summary

Nitrofurantoin is a nitrofuran-class antibacterial agent with decades of established use for acute uncomplicated urinary tract infections (UTIs). The TxGNN model predicts it may be effective for Rheumatoid Arthritis, with 0 clinical trials and 12 publications currently identified — however, critically, the available literature reveals Nitrofurantoin as a documented harm contributor in RA patients rather than a viable therapeutic candidate, and the prediction appears to reflect a reverse safety signal rather than a genuine treatment opportunity.

Quick Overview

Item	Content
Original Indication	Urinary tract infection (globally established use; no Philippines registration on file)
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	99.89%
Evidence Level	L4
Philippines Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the data sources queried. Based on well-established pharmacology, Nitrofurantoin is a prodrug activated by bacterial flavoproteins through intracellular reduction. This generates reactive intermediates that disrupt multiple bacterial targets simultaneously — bacterial DNA, ribosomal proteins, and cell wall synthesis — making resistance development unlikely. This mechanism is specific to prokaryotic cellular machinery and has no recognized anti-inflammatory or immunomodulatory activity relevant to rheumatoid arthritis.

The TxGNN knowledge graph likely constructed a link between Nitrofurantoin and RA through shared pathological territory rather than a direct therapeutic mechanism. RA patients frequently develop interstitial lung disease (RA-ILD), and Nitrofurantoin is a well-documented cause of drug-induced pulmonary fibrosis — creating a co-occurrence pattern in the clinical literature that graph-based models can misinterpret as a therapeutic signal. A 2022 case report (PMID 35145797) documents irreversible pulmonary fibrosis in a 94-year-old RA patient receiving concurrent Methotrexate and Nitrofurantoin — the combination of two pulmonary-toxic agents in a patient already at risk for RA-ILD is an active safety hazard, not a treatment rationale.

A theoretically indirect pathway exists: certain antibiotics have been shown to influence RA disease activity through gut microbiome modulation (PMID 31222078), and this self-controlled case series demonstrated that antibiotic exposure correlated with RA flare timing. However, that study examined antibiotics as a drug class using CPRD GOLD population data and did not isolate Nitrofurantoin-specific effects. Given Nitrofurantoin’s known pulmonary and hepatic toxicity profile — particularly when combined with standard RA therapies — pursuing this hypothesis would carry substantial patient safety risk without any supporting mechanistic evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35145797	2022	Case Report	Cureus	RA patient on long-term Methotrexate developed irreversible pulmonary fibrosis after Nitrofurantoin was added for chronic UTI — documents active synergistic harm signal
31222078	2019	Self-controlled Case Series	Scientific Reports	Antibiotic exposure associated with RA flare risk in 31,992-patient CPRD cohort; class-level association, no Nitrofurantoin-specific data
3335140	1988	Cohort/Retrospective	Chest	Poor prognosis documented in RA patients hospitalized for interstitial lung fibrosis; contextualizes severity of pulmonary overlap risk
15195196	2004	Review	Saudi Medical Journal	Nitrofurantoin explicitly listed among drugs causing pulmonary fibrosis; mechanism attributed to chronic administration
25362778	2014	Review	La Revue du praticien	Nitrofurantoin categorized as a causative antibiotic in drug-induced interstitial lung disease; various clinical patterns described
41635325	2026	Case Report	Cureus	Autoimmune hepatitis workup: Nitrofurantoin and methyldopa listed as medications to rule out as causes; RA and thyroiditis co-appear as autoimmune context
8104358	1993	Case Report	Revue de pneumologie clinique	Gold salt-induced pneumonia with CD4 alveolitis in RA patient — relevant parallel showing how RA drugs themselves can cause drug-ILD, compounding risk
4608019	1974	Review	Der Internist	Early synopsis of alveolitis and pulmonary fibrosis etiologies; foundational context
899886	1977	Clinical Study	Acta Medica Scandinavica	Short-term Nitrofurantoin therapy and one-year follow-up for bacteriuria in middle-aged women; establishes Nitrofurantoin’s primary UTI use context
11937933	2002	Case Report	Annales de dermatologie et de vénéréologie	Nitrofurantoin cited as a known cause of drug-induced sialadenitis; illustrates broad organ-level adverse effect profile

Philippines Market Information

Nitrofurantoin is currently not registered with the Philippine FDA. There are no licensed pharmaceutical products on record in the Philippines regulatory database.

Safety Considerations

Please refer to the package insert for safety information.

Evidence-derived safety alert (from literature review): Although formal Philippines regulatory safety data is unavailable, the published literature assembled for this prediction contains critical safety signals that directly affect the RA patient population: (1) Nitrofurantoin is a recognized cause of drug-induced pulmonary fibrosis — when combined with Methotrexate, the most commonly used first-line RA DMARD, irreversible pulmonary fibrosis has been documented (PMID 35145797); (2) RA patients are already at elevated baseline risk for interstitial lung disease (RA-ILD), meaning Nitrofurantoin exposure creates a synergistic hazard; (3) Nitrofurantoin can induce methemoglobin formation via photoactivation, posing additional risk in patients on multiple medications; (4) when creatinine clearance falls below 30 mL/min — a threshold frequently reached in patients with long-standing RA or concurrent diabetic nephropathy — urinary drug concentrations become subtherapeutic while toxic metabolite accumulation increases peripheral neuropathy risk.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction score of 99.89% reflects knowledge graph connectivity, not therapeutic validity — every piece of literature identified connects Nitrofurantoin to rheumatoid arthritis as a causative agent of harm (drug-induced pulmonary fibrosis overlapping with RA-ILD) rather than as a treatment, and the drug lacks any anti-inflammatory or immunomodulatory mechanism of action.

Broader pattern across all 10 predicted indications: This Evidence Pack reveals a consistent pattern across all TxGNN-predicted indications for Nitrofurantoin — in most cases, the knowledge graph has mistaken drug-induced adverse event co-occurrence for therapeutic signal:

Methemoglobinemia / Methemoglobinemia (alpha type) (Ranks 8 & 10): Nitrofurantoin is a documented cause of methemoglobin formation (PMID 3176031); repurposing is actively contraindicated.
Sclerosing Cholangitis (Rank 7): Nitrofurantoin is a known cause of drug-induced liver injury including cholestatic hepatitis; the drug is the perpetrator, not the treatment.
Diabetic Nephropathy (Rank 4): Literature describes antibiotic resistance patterns in UTI complicating DN — not Nitrofurantoin as a DN therapy. Active contraindication exists when CrCl <30 mL/min.
Genetic/developmental syndromes (Ranks 2, 3, 5, 6): No mechanistic plausibility. Likely graph artifacts from shared anatomical nodes (urinary tract, renal, ocular).
Gout (Rank 9): Single tangential pyelonephritis review; no therapeutic link.

To proceed with any re-evaluation, the following is needed:

Formal MOA retrieval from DrugBank API (DG002 remediation) to confirm whether any off-target anti-inflammatory activity has been characterized
Philippines FDA package insert download and parsing (DG001 remediation) to obtain official warnings and contraindications
A hypothesis-specific literature search for Nitrofurantoin and microbiome-mediated RA modulation, restricted to studies with Nitrofurantoin-specific (not class-level) endpoints
Pre-clinical toxicology review to determine whether any sub-antimicrobial dose range could exhibit immunomodulatory effects without pulmonary or hepatic toxicity — a prerequisite before any in vitro or animal studies
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.